ArticleSchizophrenia research. Cognition2026
A clinical control study of modified electroconvulsive therapy and sodium valproate as enhancement strategies for ultra-treatment-resistant schizophrenia.
Article in Schizophrenia research. Cognition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond Clozapine Failure: Precision Approach and Palliative Psychiatry in Ultra-Treatment-Resistant Schizophrenia.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A substantial proportion of patients with schizophrenia show an inadequate response to clozapine, a condition termed ultra-treatment-resistant schizophrenia (UTRS). While modified electroconvulsive therapy (MECT) and sodium valproate are common augmentation strategies, head-to-head trials directly comparing their efficacy and safety are lacking. This study aimed to directly compare the short-term efficacy and safety of MECT versus sodium valproate as augmenting agents to clozapine in patients with UTRS. Methods: This was an 8-week, single-center, randomized controlled trial. Seventy inpatients meeting diagnostic criteria for UTRS were randomly assigned to receive either MECT augmentation ( Results: At week 8, the MECT group demonstrated a significantly greater reduction in PANSS total score compared to the sodium valproate group ( Conclusion: In this cohort of inpatients with UTRS, 8 weeks of MECT augmentation appeared to be more effective than sodium valproate in reducing overall psychotic symptoms. These findings should be considered preliminary, and neither intervention demonstrated short-term benefits for cognitive function. Future studies with longer follow-up periods are warranted to assess the durability of response and should include a clozapine-only control arm to confirm the true value of these augmentation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.